SCHEMBL20744784

SCHEMBL20744784

Nc1ncnc2c1c(Cc1cccc(Cl)c1)nn2C1CC(O)C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 11/20 0.60
CSNK1A1 P48729 2/20 0.53
CSNK1D P48730 2/20 0.53
CSNK1E P49674 1/20 0.53
EGFR P00533 2/20 0.47
RET P07949 4/20 0.46
IGF1R P08069 1/20 0.46
AKT1 P31749 1/20 0.45
KDR P35968 3/20 0.44
LCK P06239 2/20 0.44
CDC7 O00311 1/20 0.44
PLK4 O00444 1/20 0.44
DYRK3 O43781 1/20 0.44
JAK2 O60674 1/20 0.44
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
NTRK1 P04629 1/20 0.44
INSR P06213 1/20 0.44
FYN P06241 1/20 0.44
CDK1 P06493 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20744798 1.00 SRC (0.60) SRCCSNK1A1CSNK1DCSNK1EEGFR
SCHEMBL20744781 1.00 SRC (0.60) SRCCSNK1A1CSNK1DCSNK1EEGFR
SCHEMBL20744772 0.90 SRC (0.60) SRCCSNK1A1CSNK1DCSNK1EEGFR
SCHEMBL20744770 0.90 SRC (0.60) SRCCSNK1A1CSNK1DCSNK1EEGFR
SCHEMBL20500111 0.89 SRC (0.65) SRCCSNK1A1CSNK1DCSNK1EEGFR
SCHEMBL20500101 0.88 SRC (0.62) SRCCSNK1A1CSNK1DCSNK1EEGFR
SCHEMBL863906 0.88 SRC (0.64) SRCCSNK1A1CSNK1DCSNK1EEGFR
SCHEMBL20744765 0.86 SRC (0.60) SRCCSNK1A1CSNK1DCSNK1EEGFR
SCHEMBL20744809 0.85 SRC (0.55) SRCCSNK1A1CSNK1DCSNK1EEGFR
SCHEMBL20744808 0.85 SRC (0.55) SRCCSNK1A1CSNK1DCSNK1EEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11518761-B2 CDPK1 inhibitors, compositions, and methods related thereto Vyera Pharmaceuticals, LLC (US) 2022-12-06 US disclosed
EP-3853230-A1 CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO Vyera Pharmaceuticals, LLC (US) 2021-07-28 EP disclosed
US-20210032240-A1 CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO Vyera Pharmaceuticals, LLC 2021-02-04 US disclosed
EP-3668875-A1 CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO Vyera Pharmaceuticals, LLC (US) 2020-06-24 EP disclosed
WO-2020061279-A1 CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO Vyera Pharmaceuticals, LLC (US) 2020-03-26 WO disclosed
WO-2019036001-A1 CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO Vyera Pharmaceuticals, LLC (US) 2019-02-21 WO disclosed
WO-2019036001-A1 CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO Vyera Pharmaceuticals, LLC (US) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11518761-B2 CDPK1 inhibitors, compositions, and methods related thereto CAMKK1, CAMK1, CAMKK2 SRC 408/4885CSNK1A1 19/4885CSNK1D 170/4885
US-20210032240-A1 CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO CAMKK1, CAMK1, CAMKK2 SRC 408/4885CSNK1A1 19/4885CSNK1D 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.